Beta-blockers have long been approached with caution in patients with asthma due to their potential to provoke bronchospasm and blunt the effects of rescue inhalers. This risk is largely driven by receptor selectivity. In this article, we will break down the best and worst beta-blockers in asthma.
Beta-Blockers in Asthma – General Principles
While nonselective beta-blockers inhibit both β1 (cardiac) and β2 (pulmonary) receptors—potentially worsening airway function—cardioselective agents primarily target β1 receptors and have a much lower impact on bronchial smooth muscle. As a result, understanding and applying beta-blocker selectivity has become a critical component of modern asthma care, allowing clinicians to balance cardiovascular benefits with respiratory safety rather than avoiding the class altogether.
The Worst
Let’s start with the worst beta-blockers in asthma. Remember that these beta-blockers are “non-selective” and will block both beta-1 and beta-2 receptors. The most commonly used non-selective beta-blocker used in practice is propranolol (excellent board exam nugget to remember). This is one of the worst agents to use in a patient whose asthma is uncontrolled. Avoid this if you can. Nadalol is another agent that is non-selective, but it is pretty seldom that I see this agent utilized in practice. Carvedilol also has alpha-blocking activity in addition to its non-selectivity on beta receptors. This one is generally avoided as well if there is concern about affecting respiratory conditions.
The Best
Bisoprolol, atenolol, and metoprolol are commonly used agents in practice that are considered cardioselective (i.e. they primarily target beta-1 receptors). In practice, I see metoprolol used the most of these agents. Metoprolol has quite a few compelling indications, and clinicians have more experience with it as well. It also has an immediate-release and extended-release formulation that is more convenient.
I do want to caution you on these principles. Selectivity is dependent upon the dose. As doses escalate, the impact on asthma could be more significant. 25 mg of metoprolol may not impact a patient’s asthma control, but 200 mg per day may cause the respiratory status to change. Clinical monitoring with initiation and dose escalation is critical when using beta-blockers in asthma.
One last point: when you see a change in asthma control, be sure to check the medication list and see if a beta-blocker has been recently started or increased. I’ve caught this scenario numerous times throughout my career when a patient loses asthma control, and in the preceding weeks, a beta-blocker was added or increased.
0 Comments